亚太地区器官排斥预防市场 – 行业趋势及 2029 年预测

Customize Your Report Customize Your Report 立即购买 立即购买 免费样本报告 免费样本报告
Home Pharmaceutical Asia Pacific Prophylaxis Of Organ Rejection Market
请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太地区器官排斥预防市场 – 行业趋势及 2029 年预测

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Asia-Pacific
  • 350 页面
  • 桌子數： 311
  • 图号： 56
立即购买 立即购买

Asia Pacific Prophylaxis Of Organ Rejection Market

市场规模（十亿美元）

CAGR :  % Diagram

Diagram Forecast Period
 2022 –2029
Diagram Market Size (Base Year)
 USD 599.21 Million
Diagram Market Size (Forecast Year)
 USD 943.85 Million
Diagram CAGR
 %
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

>亚太器官排斥预防市场按原因（流行病学暴露、抗菌预防、预防其他病原体等）、治疗（门诊免疫抑制剂、住院免疫抑制剂等）、给药途径（口服、静脉注射）、器官（肾、肝、心脏、肺、其他）、患者类型（儿科、成人）、最终用户（医院、诊所家庭医疗保健等）、分销渠道（直接招标、药店等）、亚太地区国家（日本、中国、澳大利亚、韩国、印度、新加坡、泰国、印度尼西亚、马来西亚、菲律宾和亚太地区其他地区）划分的行业趋势和预测到 2029 年。

亚太地区预防器官排斥市场

市场分析与洞察：亚太地区器官排斥预防市场

预计亚太地区器官排斥预防市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，该市场将以 6.0% 的复合年增长率增长，预计到 2029 年将从 2021 年的 5.9921 亿美元增至 9.4385 亿美元。器官移植的普及率上升和免疫抑制剂的使用增加可能是预测期内推动市场需求的主要驱动力。

预防一词是指给予治疗或采取行动来预防疾病。器官排斥的预防是指使用药物预防器官排斥。接受移植的患者必须接受免疫抑制治疗以预防排斥，以确保移植物存活。移植排斥是一个过程，在此过程中，移植接受者的免疫力会下降。目前的排斥预防措施包括使用钙调磷酸酶抑制剂、mTOR 抑制剂、抗代谢药物和皮质类固醇。治疗药物可以改善器官移植的短期后果，但有一定的改善。接受实体器官移植的接受者应服用抗排斥药物。这是因为免疫系统会破坏移植的器官。

推动亚太地区器官排斥预防市场增长的因素包括器官移植的普及、外科手术的增多、接受者人口的增加以及产品的推出。然而，预计会制约市场的因素包括移植手术成本的上升、对器官移植缺乏认识以及患者接受移植器官时存在的风险。

另一方面，市场参与者的战略举措、研发的增加以及免疫抑制剂的使用可能为亚太地区器官排斥预防市场的增长提供机会。对熟练专业知识和监管部门批准的需求可能会给亚太地区器官排斥预防市场带来挑战。亚太地区器官排斥预防市场最近出现了一些发展。

亚太地区器官排斥预防市场报告提供了市场份额、新发展和国内和本地市场参与者影响的详细信息，分析了新兴收入来源、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预​​期目标。

亚太地区预防器官排斥市场

亚太地区预防器官排斥市场范围和市场规模

亚太地区器官排斥预防市场根据原因、治疗给药途径、器官、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

亚太地区器官排斥预防市场分为七个部分：原因、治疗、给药途径、器官、患者类型、最终用户和分销渠道。

  • 根据原因，亚太地区器官排斥预防市场细分为流行病学暴露、抗菌预防、针对其他病原体的预防和其他。2022 年，流行病学暴露部分预计将在亚太地区器官排斥预防市场中占据主导地位，因为中国存在与器官排斥预防相关的病原体，并且有直接信息可供获取
  • 根据治疗方式，亚太地区器官排斥预防市场细分为门诊免疫抑制剂、住院免疫抑制剂和其他。2022 年，门诊免疫抑制剂市场预计将在亚太地区器官排斥预防市场占据主导地位，因为它可以实现对受损细胞的持续和特异性免疫反应，并且上海地区环孢菌素的可用性。
  • 根据给药途径，亚太地区器官排斥预防市场分为口服和静脉注射。2022 年，由于口服片剂和胶囊的供应量和摄入量增加，口服药物预计将在亚太地区器官排斥预防市场中占据主导地位。
  • 根据器官，亚太地区器官排斥预防市场细分为肾脏、肝脏、心脏、肺脏和其他器官。2022 年，由于肾衰竭发病率增加以及接受者保险的医疗保险等报销政策的存在，预计肾脏领域将在亚太地区器官排斥预防市场中占据主导地位。
  • 根据患者类型，亚太地区器官排斥预防市场分为儿科和成人。2022 年，成人市场预计将在亚太地区器官排斥预防市场中占据主导地位，这是由于成人患者慢性病和遗传疾病的患病率增加、成人免疫系统较弱以及新墨西哥州和美国成人接受者的等候名单比儿童和妇女的等候名单要多
  • 根据最终用户，亚太地区器官排斥预防市场分为医院、诊所、家庭医疗保健和其他。到 2022 年，医院部门预计将在亚太地区器官排斥预防市场中占据主导地位，因为医疗保健水平的提高以及与亚太地区其他医院合作向接受患者提供捐赠器官预计将占据市场主导地位。
  • 根据分销渠道，亚太地区器官排斥预防市场分为直接招标、药店和其他。到 2022 年，由于制药公司对门诊免疫抑制剂的需求激增，预计直接招标市场将主导亚太地区器官排斥预防市场，并且保证付款将主导市场。

亚太地区器官排斥预防市场国家级分析

亚太地区器官排斥预防市场根据原因、治疗给药途径、器官、最终用户和分销渠道进行细分。

预防器官排斥市场报告涉及的国家包括中国、日本、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾和亚太地区其他地区。

预计亚太地区将在预测期内以最高的复合年增长率增长，因为随着城市化和实验室自动化的发展，亚太地区国家对预防器官排斥产品的需求正在迅速增长。预计中国将在亚太市场占据主导地位。由于等待器官移植的患者人数增加以及外科手术增加，中国是预防器官排斥市场的主要国家之一。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了亚太地区品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。  

新兴经济体器官排斥预防的增长潜力和市场参与者的战略举措正在为亚太器官排斥预防市场创造新的机遇 

 亚太地区器官排斥预防市场还为您提供每个国家/地区特定行业器官排斥预防销售增长的详细市场分析、器官排斥预防领域进步的影响以及监管环境的变化及其对器官排斥预防市场的支持。数据适用于 2020 年至 2021 年的历史时期。

竞争格局和亚太地区预防器官排斥的市场份额分析

亚太地区器官排斥预防市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司在器官排斥预防市场的重点相关。

亚太地区提供器官排斥预防治疗的主要公司包括 Concord Biotech、Panacea Biotec、WOCKHARDT、Astellas Pharma Inc、Novartis AG、Bristol-Myers Squibb Company、Dr Reddy's Laboratories, Ltd、Viatris Inc、Strides Pharma Science Limited、Glenmark、Biocon、Pfizer Inc、Mayne Pharma Group Limited、Hikma Pharmaceuticals PLC、AbbVie Inc、Apotex Inc、Pharmaceuticals LLC、Zydus Pharmaceuticals, Inc.、浙江海正药业有限公司、CSL Behring 等。

DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

市场参与者的战略举措以及预防器官排斥的新技术进步正在弥补慢性伤口治疗的差距。 

例如，

  • 2021 年 9 月，诺华公司停止了 CFZ533（iscalimab）在肾移植患者中的 CIRRUS-1 研究。分析表明，与他克莫司治疗相比，CFZ533（iscalimab）治疗在预防肾移植患者器官排斥方面效果较差。临床试验停止将导致该药物的审批延迟。

市场参与者的合作、合资和其他策略正在增强公司在器官排斥预防市场中的市场，这也为组织改善其在器官排斥预防市场中的产品供应提供了好处。

 

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 BY CAUSE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: EPIDEMIOLOGY SNAPSHOT

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISE IN PREVALENCE OF ORGAN TRANSPLANTATIONS

5.1.2 RISE IN CHRONIC DISEASES

5.1.3 RISE IN CLINICAL TRIALS

5.1.4 RISE IN RECIPIENT PATIENTS

5.1.5 PRODUCT APPROVALS

5.2 RESTRAINTS

5.2.1 RISE IN COST OF TRANSPLANTATION PROCEDURE

5.2.2 LACK OF AWARENESS ABOUT ORGAN TRANSPLANTATION

5.2.3 RISKS INCLUDED WITH THE PATIENT RECEIVES TRANSPLANTED ORGAN

5.2.4 ETHICAL ISSUES RELATED TO ORGAN TRANSPLANTATION

 

5.3 OPPORTUNITIES

5.3.1 RISE IN RESEARCH AND DEVELOPMENTS

5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

5.3.3 RISE IN USE OF IMMUNOSUPPRESSANT

5.4 CHALLENGES

5.4.1 SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE USE OF PROPHYLAXIS OF ORGAN REJECTION

5.4.2 STRINGENT REGULATIONS

6 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE

6.1 OVERVIEW

6.2 EPIDEMIOLOGIC EXPOSURE

6.2.1 HOSPITAL EXPOSURE

6.2.2 COMMUNITY EXPOSURE

6.3 ANTIBACTERIAL PROPHYLAXIS

6.3.1 POST-TRANSPLANT PROPHYLAXIS

6.3.2 PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS

6.4 PROPHYLAXIS AGAINST OTHER PATHOGENS

6.5 OTHERS

7 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT

7.1 OVERVIEW

7.2 OUTPATIENT IMMUNOSUPPRESSANT

7.2.1 CALCINEURIN INHIBITORS

7.2.1.1 CYCLOSPORINE

7.2.1.2 TACROLIMUS

7.2.1.2.1 IMMEDIATE RELEASE

7.2.1.2.2 EXTENDED RELEASE

7.2.2 CORTICOSTEROIDS

7.2.2.1 METHYLPREDNISOLONE

7.2.2.2 PREDNISONE

7.2.2.3 OTHERS

7.2.3 MYCOPHENOLIC ACIDS

7.2.3.1 MYCOPHENOLATE MOFETIL

7.2.3.2 MYCOPHENOLATE SODIUM

7.2.4 MTOR INHIBITORS

7.2.4.1 SIROLIMUS

7.2.4.2 EVEROLIMUS

7.2.5 AZATHIOPRINE

7.2.6 OTHERS

 

7.3 INPATIENT IMMUNOSUPPRESSANT

7.3.1 BELATACEPT

7.3.2 BASILIXIMAB

7.3.3 OTHERS

7.4 OTHERS

7.4.1 ERYTHROPOIESIS-STIMULATING AGENTS

7.4.1.1 ERYTHROPOIETIN

7.4.1.2 DARBEPOETIN

7.4.2 ANTI-VIRAL AGENTS

7.4.2.1 VALGANCICLOVIR

7.4.2.2 LAMIVUDINE

7.4.2.3 ADEFOVIR

7.4.2.4 OTHERS

7.4.3 OTHERS

8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW

8.2 ORAL

8.2.1 TABLET

8.2.1.1 IMMEDIATE RELEASE

8.2.1.2 EXTENDED-RELEASE

8.2.2 ORAL SOLUTION

8.2.3 OTHERS

8.3 INTRAVENOUS

9 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN

9.1 OVERVIEW

9.2 KIDNEY

9.3 LIVER

9.4 HEART

9.5 LUNG

9.6 OTHERS

10 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 ADULTS

10.3 PEDIATRIC

 

11 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICS

11.4 HOME HEALTHCARE

11.5 OTHERS

12 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 PHARMACY STORES

12.3.1 HOSPITAL PHARMACY

12.3.2 RETAIL PHARMACY

12.3.3 ONLINE PHARMACY

12.4 OTHERS

13 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION

13.1 ASIA-PACIFIC

13.1.1 CHINA

13.1.2 JAPAN

13.1.3 SOUTH KOREA

13.1.4 INDIA

13.1.5 AUSTRALIA

13.1.6 THAILAND

13.1.7 MALAYSIA

13.1.8 PHILIPPINES

13.1.9 SINGAPORE

13.1.10 INDONESIA

13.1.11 VIETNAM

13.1.12 REST OF ASIA-PACIFIC

14 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

15 QUESTIONNAIRE

16 RELATED REPORTS

表格列表

TABLE 1 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 2 ASIA PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC PROPHYLAXIS AGAINST OTHER PATHOGENS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC INTRAVENOUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC KIDNEY IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC LIVER IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC HEART IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC LUNG IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC ADULTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC PEDIATRIC IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC HOSPITALS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC CLINICS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA PACIFIC HOME HEALTHCARE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 ASIA PACIFIC DIRECT TENDERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 ASIA PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 ASIA PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 ASIA PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 53 ASIA-PACIFIC TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 54 ASIA-PACIFIC MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 ASIA-PACIFIC MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 56 ASIA-PACIFIC CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 57 ASIA-PACIFIC INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 58 ASIA-PACIFIC OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 ASIA-PACIFIC ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 60 ASIA-PACIFIC ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 61 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 62 ASIA-PACIFIC ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 63 ASIA-PACIFIC TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 64 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 65 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 66 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 67 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 68 ASIA-PACIFIC PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 70 CHINA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 71 CHINA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 72 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 73 CHINA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 74 CHINA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 75 CHINA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 76 CHINA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 77 CHINA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 78 CHINA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 79 CHINA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 80 CHINA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 81 CHINA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 82 CHINA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 83 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 84 CHINA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 85 CHINA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 86 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 87 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 88 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 89 CHINA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 CHINA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 92 JAPAN EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 93 JAPAN ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 94 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 95 JAPAN OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 96 JAPAN CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 97 JAPAN TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 98 JAPAN MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 99 JAPAN MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 100 JAPAN CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 101 JAPAN INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 102 JAPAN OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 103 JAPAN ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 104 JAPAN ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 105 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 106 JAPAN ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 JAPAN TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 108 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 109 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 110 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 111 JAPAN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 112 JAPAN PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 114 SOUTH KOREA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 115 SOUTH KOREA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 116 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 117 SOUTH KOREA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 118 SOUTH KOREA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 119 SOUTH KOREA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 120 SOUTH KOREA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 121 SOUTH KOREA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 122 SOUTH KOREA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 123 SOUTH KOREA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 124 SOUTH KOREA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 125 SOUTH KOREA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 126 SOUTH KOREA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 127 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 128 SOUTH KOREA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 129 SOUTH KOREA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 130 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 131 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 132 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 133 SOUTH KOREA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 134 SOUTH KOREA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 135 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 136 INDIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 137 INDIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 138 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 139 INDIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 140 INDIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 141 INDIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 142 INDIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 143 INDIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 144 INDIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 145 INDIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 146 INDIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 147 INDIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 148 INDIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 149 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 150 INDIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 151 INDIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 152 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 153 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 154 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 155 INDIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 156 INDIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 157 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 158 AUSTRALIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 159 AUSTRALIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 160 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 161 AUSTRALIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 162 AUSTRALIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 163 AUSTRALIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 164 AUSTRALIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 165 AUSTRALIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 166 AUSTRALIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 167 AUSTRALIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 168 AUSTRALIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 169 AUSTRALIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 170 AUSTRALIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 171 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 172 AUSTRALIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 AUSTRALIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 174 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 175 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 176 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 177 AUSTRALIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 178 AUSTRALIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 179 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 180 THAILAND EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 181 THAILAND ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 182 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 183 THAILAND OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 184 THAILAND CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 185 THAILAND TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 186 THAILAND MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 187 THAILAND MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 188 THAILAND CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 189 THAILAND INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 190 THAILAND OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 191 THAILAND ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 192 THAILAND ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 193 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 194 THAILAND ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 195 THAILAND TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 196 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 197 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 198 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 199 THAILAND PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 200 THAILAND PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 201 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 202 MALAYSIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 203 MALAYSIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 204 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 205 MALAYSIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 206 MALAYSIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 207 MALAYSIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 208 MALAYSIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 209 MALAYSIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 210 MALAYSIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 211 MALAYSIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 212 MALAYSIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 213 MALAYSIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 214 MALAYSIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 215 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 216 MALAYSIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 217 MALAYSIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 218 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 219 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 220 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 221 MALAYSIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 222 MALAYSIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 223 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 224 PHILIPPINES EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 225 PHILIPPINES ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 226 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 227 PHILIPPINES OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 228 PHILIPPINES CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 229 PHILIPPINES TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 230 PHILIPPINES MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 231 PHILIPPINES MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 232 PHILIPPINES CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 233 PHILIPPINES INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 234 PHILIPPINES OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 235 PHILIPPINES ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 236 PHILIPPINES ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 237 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 238 PHILIPPINES ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 239 PHILIPPINES TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 240 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 241 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 242 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 243 PHILIPPINES PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 244 PHILIPPINES PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 245 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 246 SINGAPORE EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 247 SINGAPORE ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 248 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 249 SINGAPORE OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 250 SINGAPORE CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 251 SINGAPORE TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 252 SINGAPORE MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 253 SINGAPORE MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 254 SINGAPORE CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 255 SINGAPORE INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 256 SINGAPORE OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 257 SINGAPORE ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 258 SINGAPORE ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 259 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 260 SINGAPORE ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 261 SINGAPORE TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 262 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 263 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 264 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 265 SINGAPORE PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 266 SINGAPORE PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 267 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 268 INDONESIA EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 269 INDONESIA ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 270 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 271 INDONESIA OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 272 INDONESIA CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 273 INDONESIA TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 274 INDONESIA MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 275 INDONESIA MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 276 INDONESIA CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 277 INDONESIA INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 278 INDONESIA OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 279 INDONESIA ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 280 INDONESIA ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 281 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 282 INDONESIA ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 283 INDONESIA TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 284 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 285 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 286 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 287 INDONESIA PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 288 INDONESIA PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 289 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 290 VIETNAM EPIDEMIOLOGIC EXPOSURE IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 291 VIETNAM ANTIBACTERIAL PROPHYLAXIS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY CAUSE, 2020-2029 (USD MILLION)

TABLE 292 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 293 VIETNAM OUTPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 294 VIETNAM CALCINEURIN INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 295 VIETNAM TACROLIMUS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 296 VIETNAM MYCOPHENOLIC ACIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 297 VIETNAM MTOR INHIBITORS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 298 VIETNAM CORTICOSTEROIDS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 299 VIETNAM INPATIENT IMMUNOSUPPRESSANT IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 300 VIETNAM OTHERS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 301 VIETNAM ERYTHROPOIESIS-STIMULATING AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 302 VIETNAM ANTI-VIRAL AGENTS IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 303 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 304 VIETNAM ORAL IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 305 VIETNAM TABLET IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 306 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY ORGAN, 2020-2029 (USD MILLION)

TABLE 307 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)

TABLE 308 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 309 VIETNAM PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 310 VIETNAM PHARMACY STORES IN PROPHYLAXIS OF ORGAN REJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 311 REST OF ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: DBMR POSITION GRID

FIGURE 8 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED PREVALENCE OF ORGAN TRANSPLANTATION, RISE IN RECIPIENT PATIENTS, AND PRODUCT APPPROVALS ARE EXPECTED TO DRIVE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 TO 2029

FIGURE 13 EPIDEMIOLOGIC EXPOSURE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET FROM 2022 & 2029

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PROPHYLAXIS OF ORGAN REJECTION MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE, 2021

FIGURE 16 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: INCIDENCE REGIONAL LEVEL, 2021

FIGURE 17 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: PREVALENCE (2018-2021) AT REGIONAL LEVEL SNAPSHOT

FIGURE 18 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION: SURVIVAL OF PATIENT SNAPSHOT

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET

FIGURE 20 INCREASE COUNT OF KIDNEY TRANSPLANTATIONS IN THE U.S., 2020

FIGURE 21 TOTAL NUMBER OF ORGAN TRANSPLANTATION IN THE ASIA PACIFIC SCENARIO, 2020

FIGURE 22 TOTAL NUMBER OF PATIENTS ON WAITING LIST VS TRANSPLANTS PERFORMED BY ORGAN IN 2020

FIGURE 23 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2021

FIGURE 24 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, 2020-2029 (USD MILLION)

FIGURE 25 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, CAGR (2022-2029)

FIGURE 26 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 27 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2021

FIGURE 28 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, 2020-2029 (USD MILLION)

FIGURE 29 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 30 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 31 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 32 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 33 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 34 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2021

FIGURE 36 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, 2020-2029 (USD MILLION)

FIGURE 37 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, CAGR (2022-2029)

FIGURE 38 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY ORGAN, LIFELINE CURVE

FIGURE 39 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2021

FIGURE 40 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, 2020-2029 (USD MILLION)

FIGURE 41 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 42 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 43 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2021

FIGURE 44 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 45 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, CAGR (2022-2029)

FIGURE 46 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 48 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 49 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 50 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: SNAPSHOT (2021)

FIGURE 52 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021)

FIGURE 53 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2022 & 2029)

FIGURE 54 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY COUNTRY (2021 & 2029)

FIGURE 55 ASIA-PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: BY CAUSE (2022-2029)

FIGURE 56 ASIA PACIFIC PROPHYLAXIS OF ORGAN REJECTION MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on Asia-Pacific Prophylaxis Of Organ Rejection Market By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others.), Treatment(Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), By Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Paediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), By  Country Asia-Pacific (Japan, China, Australia, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, & Rest Of Asia-Pacific) Industry Trends And Forecast To 2029. .
The Asia Pacific Prophylaxis Of Organ Rejection Market size was valued at USD 599.21 USD Million in 2021.
The Asia Pacific Prophylaxis Of Organ Rejection Market is projected to grow at a CAGR of 6% during the forecast period of 2022 to 2029.

浏览相关页面

Banner